Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa
Open Access
- 10 January 2019
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 380 (2), 121-131
- https://doi.org/10.1056/nejmoa1813598
Abstract
Hydroxyurea is an effective treatment for sickle cell anemia, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in low-resource settings. We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-Saharan countries. Children received hydroxyurea at a dose of 15 to 20 mg per kilogram of body weight per day for 6 months, followed by dose escalation. The end points assessed feasibility (enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and benefits (laboratory variables, sickle cell–related events, transfusions, and survival). A total of 635 children were fully enrolled; 606 children completed screening and began receiving hydroxyurea at a mean (±SD) dose of 17.5±1.8 mg per kilogram per day. The retention rate was 94.2% at 3 years of treatment. Hydroxyurea therapy led to significant increases in both the hemoglobin and fetal hemoglobin levels. Dose-limiting toxic events regarding laboratory variables occurred in 5.1% of the participants, which was below the protocol-specified threshold for safety. During the treatment phase, 20.6 dose-limiting toxic effects per 100 patient-years occurred, as compared with 20.7 events per 100 patient-years before treatment. As compared with the pretreatment period, the rates of clinical adverse events decreased with hydroxyurea use, including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patient-years; incidence rate ratio, 0.45; 95% confidence interval [CI], 0.37 to 0.56), nonmalaria infection (142.5 vs. 90.0 events per 100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72), malaria (46.9 vs. 22.9 events per 100 patient-years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), transfusion (43.3 vs. 14.2 events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and death (3.6 vs. 1.1 deaths per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88). Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive events, infections, malaria, transfusions, and death, which supports the need for wider access to treatment. (Funded by the National Heart, Lung, and Blood Institute and others; REACH ClinicalTrials.gov number, NCT01966731.)Keywords
Funding Information
- National Heart, Lung, and Blood Institute (K23 HL128885, U01 HL133883)
- Cincinnati Children’s Research Foundation (None)
This publication has 37 references indexed in Scilit:
- Is Sickle Cell Anemia a Neglected Tropical Disease?PLoS Neglected Tropical Diseases, 2013
- The effect of hydroxcarbamide therapy on survival of children with sickle cell diseaseBritish Journal of Haematology, 2013
- Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimatesThe Lancet, 2013
- Foetal haemoglobin and the dynamics of paediatric malariaMalaria Journal, 2012
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of KenyaBlood, 2010
- How I use hydroxyurea to treat young patients with sickle cell anemiaBlood, 2010
- Improved survival of children and adolescents with sickle cell diseaseBlood, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaThe New England Journal of Medicine, 1995